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Introduction: Adjuvant local-regional radiotherapy (LRRT) is routinely recommended for breast cancer patients. It is
well known being related to pulmonary side-effects. We studied post-RT radiological changes on X-ray and CT, and
correlated the findings with Quality of Life (QoL), common dosimetric factors and co-variates. The results were
compared with a previously reported cohort of 137 irradiated women.
Methods: 88 women underwent chest X-ray and CT pre-and 4-5 months after 3-D planned LRRT, minimizing the
dose to the ipsilateral lung to V20 < 30%. The lung field was divided into 3 regions and the development of post-
RT density changes were graded (0-3). Patients with radiological changes were compared with non-responders.
Clinical symptoms were registered and data on patient and treatment related co-variates were gathered
prospectively. The ipsilateral lung dosimetric factors V13,V 20,V 30 and mean dose were calculated and QoL was
assessed before and 4 months after RT.
Results: The use of dose-volume constraints significally reduced moderate-severe radiological changes on chest X-ray
compared with our earlier study (Chi square trend test: p < 0.001). Symptomatic pneumonitis was also rare in the
present study. No agreement was found between CT and chest X-ray as diagnostic tools for post-RT pneumonitis. V13
correlated independently with radiological changes on CT (logistic regression: p = 0.04; ROC area: 0.7). The Co-variates
smoking habits, age, chemotherapy, endocrine or trastuzumab therapy did not influence the outcome on multivariate
analysis. QoL changes in physical function, i.e. fatigue, dyspnoea were not detected but there was a trend for a worse
recovery after chemotherapy in patients with high V13 (Spearman Rank Correlation: p < 0.05).
Conclusions: The use of dose-volume constraints significantly reduced post-RT radiological changes on chest X-ray
in LRRT for BC. The lung changes on CT were also generally limited when we used this strategy and was not
always picked up on chest X-ray. Variation in V13 alone was correlated with occurrence of lung changes on CT.
Introduction
Postoperative radiotherapy (RT) for breast cancer (BC)
plays an important role for reducing the rates of local
recurrence and death [1-3]. The treatment, however, deli-
vers some unwanted irradiation to the lung and heart.
Side-effects to the lungs are in the form of acute pneumo-
nitis and sub acute/late lung fibrosis. The risk for acute
and chronic RT-induced lung morbidity is influenced by
total dose, dose per fraction and irradiated lung volume.
When a 3-D RT-planning technique is used, it is possible
to quantify and limit the amount of individually irradiated
lung volume. Clinical data suggest that a total lung dose of
more than 20 Gy given with conventional fractionation
should be avoided if the unirradiated lung volume is not
sufficient to guarantee essential breathing function [4]. In
our previous work, we found no case of moderate sympto-
matic radiation pneumonitis (RP) in patients who received
doses ≥ 20 Gy (V20) to less than 30% of the ipsilateral lung
volume [5]. We therefore used this cut-off level in the pre-
sent trial. Other groups have found relations between che-
motherapy [6,7] and tamoxifen intake [8] and RT-induced
lung toxicity. In previous studies we have also found an
association with age [5,9]. Individual sensitivity to irradia-
tion is also known but a rare genetic condition in the
population[10]. However it is shown that possessions of
specific genes variants is predictive for the development of
adverse effects after radiotherapy [11-13]. In contrast
smoking has been reported to reduce the risk of RT-
induced pneumonitis [14]. Side-effects to the normal lung
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with symptoms of fever, dyspnoea and cough [15]. Signs
of interstitial pulmonary inflammation can be detected on
chest radiography (X-ray) in the irradiated lung. A later
phase with fibrosis can be detected from 20 weeks and
after about 36 weeks stationary fibrosis is obtained [16,17].
This study was performed to evaluate radiological
pneumonitis (RP) on X-ray and CT in irradiated breast
cancer women when the lung dose-volume constraints
of V20 < 30% was used and to correlate the findings
with common dosimetric factors (ipsilateral V13,V 20,
V30, MLD), Quality of life (QoL)-effects, symptoms and
co-variates and compare the outcome to a previously
reported study of 137 irradiated women [9].
Methods
This study was approved by the local ethics committee.
Participating women gave informed consent before
study enrolment.
Study population
All women who were referred to the Radiotherapy
Department at Stockholm Söder Hospital during 2003-
2005 for adjuvant LRRT after surgery for early breast
cancer were asked to participate in this trial. Ninety-five
patients were included, but seven patients withdrew
their consent due to early relapse and were not evalu-
able. Eighty-eight patients were thus followed for seven
months after RT for symptoms of acute/subacute radia-
tion induced pulmonary complication. Mastectomy was
done in 69 patients, while 19 patients were operated
with conservative breast surgery. Seventy-two patients
were irradiated with LRRT to the chest wall or breast,
axilla and supraclavicular region and in these patients
the internal mammary lymph nodes (IMN) were
included. A total of 16 patients received RT excluding
the IMN, i.e. 9 patients were given irradiation to the
breast, axilla and supraclavicular region and 7 patients
were referred for RT to the axilla and supraclavicular
fossa only.
The mean age of the patients was 56 years (range 32-81).
Data on potential confounding factors were collected
prospectively, i.e. history of cardio vascular or pulmonary
co-morbidity, smoking habits, functional level (i.e. not
being able to climb three flights of stairs without a rest
due to shortness of breath) and adjuvant hormonal-, tras-
tuzumab- and chemotherapy treatment.
The chemotherapy was concluded 3-4 weeks prior
to RT. Concurrent chemotherapy was never given. The
typically regime consisted of doxorubicin, cyclophospha-
mide and 5-fluorouracil, but in 28 patients the therapy
included docetaxel. Five patients received trastuzumab
during RT. Intake of tamoxifen and anastrozol during
RT was evenly split among the women.
To asses and evaluate Quality of life (QoL) before and
after RT we used the EORTC QLQ-C30 version 3.0 and
the EORTC QLQ-BR23 questionnaires.
Radiotherapy treatment techniques
The used RT treatment techniques are described in
detail in an earlier publication [18]. LRRT after mastect-
omy was delivered with an anterior electron beam cov-
ering the chest wall and the IMN (range 6-12 MeV) and
with a 6 MV photon beam covering the supraclavicular
region. LRRT after partial mastectomy consisted of two
tangential photon beams of 4 or 6 MV including the
breast parenchyma (50 Gy) and the regional lymph
nodes were treated in a similar way as described above
(46 Gy). An additional oblique electron beam was added
to include the IMN (46 Gy) in four cases. The pre-
scribed dose was given in daily fractions of 2 Gy, five
days a week. In the present study all patients underwent
3-D dose treatment planning (Pinnacle; version 6.2b)
with avoidance of a dose exciding 20 Gy to more than
30% of the ipsilateral lung volume but with a good cov-
erage of the clinical target volume (CTV). The cumula-
tive dose-volume histograms were calculated and the
ipsilateral lung volume receiving ≥ 13 Gy (V13), >20 Gy
(V20), >30 Gy (V30) and mean lung dose were defined.
Monitoring for symptomatic pneumonitis and evaluation
of radiological pneumonitis on X-ray and CT with the
Arrigada’s classification
All patients were followed for respiratory symptoms, i.e.
cough, dyspnoea with or without fever, 1, 4 and 7 months
after the termination of RT. The patients were classified
into three groups according to CTC-criteria (version 2.0)
[19].
0. No complications: no registered respiratory symp-
toms monitored by the clinician.
1. Mild reaction: cough and/or dyspnoea with our
without fever judged to be radiation induced.
2. Moderate reaction: same as 1 but with impaired
daily functions and treated with corticosteroids.
CT of the thorax was performed before and 4 months
after RT and standardized chest X-ray was conducted
after 5 months and evaluated by the same specialist in
diagnostic radiology (HB) as in our previous trial [5].
The reproducibility of this scoring system was validated
in our earlier publication [5].
On the frontal chest radiograph the lung was divided
into the three regions suggested by Arrigada, i.e. the apical-
lateral (A-L), central-parahilar (C-P) and basal-lateral (B-L)
regions [19]. The border between the A-L and B-L regions
was set at the level of the pulmonary artery. The width of
the C-P region was set to 5 cm and the upper and lower
border were set two vertebrae above and below the level of
pulmonary artery, respectively. Radiological pneumonitis
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The highest-density grade in each region, i.e. 0 = no evi-
dence of fibrosis, 1 = linear streaks, 2 = moderate opacifica-
tion, 3 = complete opacification were added together to
form total scores ranging from 0 to 9. Total scores of 1-3
were considered to represent slight radiological RP and
score of 4-9 moderate to severe RP. This method has been
described in detail in our earlier study [5].
Evaluation of Quality of life
We used the European Organisation for Research and
Treatment of Cancer (EORTC) form QLQ-30 (version
3.0) [20] and the EORTC QLQ-BR-23 to asses QoL [21].
The forms were completed at baseline prior to and 4
months after RT. The QLQ-30 questionnaires consist of
a total of 30 items. Five functional scales (physical, role,
cognitive, emotional and social); nine symptom scales
(fatigue, nausea/vomiting, pain, dyspnea, insomnia, appe-
tite loss, constipation, diarrhea and financial difficulties)
and one Global health status. QLQ-BR23 includes 23
items assessing disease sympto m s ,t h e r a p ys i d ee f f e c t s
such as breast, arm symptom, hair loss, body image, sex-
ual functioning, sexual enjoyment and future perspective.
Eighty-one patients completed both measurements. In
seven cases the pts did not receive the 2
nd form. The
form was double-sided and in some cases not completed
on the back page. Scoring was performed in according
with the EORTC scoring manual. Statistics and missing
data were handled according to the manual. A four-
point response scale was used to asses each item con-
cerning functions or symptoms from 1 (not at all) to 4
(very much), and a seven-point scale was used for global
health status/QoL from 1 (very poor) to 7 (excellent).
The scale scores were linearly transformed into scores
of 0-100 according to the EORTC manual. A high score
on the global health status/functional scale represents a
high/healthy level of functioning. In contrast a high
score on the symptom scale represents a high level of
symptomatology/problems. A study of the subjective sig-
nificance of changes in QoL scores has suggested that a
mean change of 5 to 10 on the multi-item scales is per-
ceived as little change, 10 to 20 as moderate change and
greater than 20 as very much change. Greater than ten
points on the transformed questionnaire scale were con-
sidered clinically meaningful [22,23].
In the present paper, three functional scales (physical
functioning, role functioning and social functioning) and
four symptom scales (fatigue, pain, dyspnoea and insomnia)
were included from QLQ C-30. In the EORTC QLQ-BR23
form we included functional scales (future perspective).
Statistical methods
The relation between symptomatic and radiological RP
and the relation between radiological RP and the
dosimetric factors and co-variates was analyzed with uni-
variate and multivariate logistic regression (Wald-Enter
method). Chi square trend test was used for test of corre-
lation between radiological RP on X-ray in the present and
earlier studies. To test agreement between CT-and X-ray
for the diagnosis of radiological RP, Kappa-statistics was
used.
Receiver operating characteristics curves (ROC) were
used to predict radiological RP with V13 [24]. Changes
in QoL-scores in relation with V13 were evaluated with
Spearman Rank Correlation. All reported results were
based on two-sided tests and p-values < 0.05 were con-
sidered statistically significant.
Results
Radiological and symptomatic radiation pneumonitis
Figure 1 shows an example of post-RT radiological RP
of grade 3 in the apical-lateral region of the left lung on
chest X-ray (= total score 3). Symptomatic pneumonitis
was very rare in this study. Only one patient developed
a moderate reaction and was treated with corticosteroids
and antibiotics, mild reactions were detected in 6
patients. There was, furthermore, no relation between
symptomatic RP and radiological RP on chest X-ray or
CT. Minor changes are not seen on chest X-ray, in due
to that CT is a more sensitive method than X-ray to
detect small effected areas of pulmonary changes.
The use of dose-volume constraints significally
reduced moderate-severe radiological RP on X-ray com-
pared with the earlier treatment series for the technique
with LRRT + IMN (Chi square trend test p < 0.001)
(Table 1). There was, however, no difference when we
compared the outcome for the technique LRRT-IMN in
Figure 1 Example of grade 3 RP in the apical-lateral region of
the left lung on chest x-ray. (= total score 3).
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mean V20 for responders and non-responding patients
a r es h o w ni nF i g u r e2 .T h ea v e r a g eV 20 and MLD in
our previous study was 35% and 16 Gy, respectively
[25]. We found no correlation between any dosimetric
factor or the studied co-variates and RP on chest X-ray
(score 0 vs score 1-9) (logistic regression). In the pre-
ceding univariate analysis there was a borderline relation
with radiological RP and anastrazol but this relation was
thus not detected on the subsequent multivariate analy-
sis which included the dosimetric factors and other
co-variates.
There was no agreement between X-ray and CT as
diagnostic tools for post-radiological RP, (Kappa test)
(Table 2). V13 was most strongly and independently
related with radiological changes on CT (score 0 vs 1-9)
(logistic regression: p = 0.04; ROC-area: 0.7) [24]. No
other factor was related to RP on CT. Table 3 shows
the correlation between the dosimetric factors in this
study. V13 was stronger correlated to MLD than V20.
Quality of life
Most of the side effects from RT appeared to have little
effect on QoL in the present trial. Chemotherapy was
concluded 3-4 weeks prior to RT and the patients started
with a higher score on fatigue at baseline due to this.
The variables role functioning, social functioning and
future perspective, were improved 4 months after RT
compared to baseline (Table 4). Physical functioning,
appeared not to be affected by RT. There were no
changes for pain and dyspnoea after RT in this series.
Patients with high V13 appeared however not recover
equally well. However, insomnia showed a trend to
increase after RT (Table 4). When changes in the indivi-
dual QLQ-variates fatique and dyspnoea were related to
V13 (Spearman correlation) there was thus a negative
correlation. There was a significant correlation between
high V13 and difficulties to take short walks, which
could be of clinical significance, and the correlation was
reported also when patients rated there overall total
quality of life during the last week.
Discussion
Clinically significant radiological and symptomatic RP
was rare in this study when 3-D treatment planning,
aiming at minimizing V20 to the ipsilateral lung to <30%
was used for LRRT in early breast cancer. The result
indicates that the used dose-volume constraints signifi-
cantly reduced moderate-severe radiological RP on chest
X-ray, in the present series, compared to our previous
study [25]. The lung changes could not always be
detected on chest X-ray and were also infrequent and
generally limited on CT when this strategy was used.
Variation in dosimetry alone (V13) was correlated with
occurrence of radiological RP on CT. ROC analyses was
performed, yet the area under the curve was only 0.7
which is not an ideal predictive value [24]. Co-variates
Table 1 Relation between radiological changes and
treatment techniques in the present and previous studies
Technique LRRT+ IMN; n LRRT-IMN; n
Arrigada’s classification scores 0 1-3 4-9 0 1-3 4-9
Present study 60 11 1 5 4 0
Previous study 58 38 20 12 9 0
Chi square trend
test p < 0.001
Chi square trend
test p = 0.9
Figure 2 Mean lung dos volume histograms (DVH) in patients
with or without RP on chest X-ray.
Table 2 Relation between radiological scores on X-ray
and CT in the present series
CT score
X-ray score 0 1-3 4-9 Total
01 3 2 5 1 2 5 0
1-3 1 7 3 11
4-9 0 1 0 1
Total 14 33 15 62
Kappa statistics: p = 0.3
Table 3 Correlation between lung dosimetric factors in
breast cancer irradiation
V13 V20 V30 Mean
V13 Pearsson Correlation 1 .925** .619** .975**
Sig. (2-tailed) .000 .000 .000
V20 Pearsson Correlation .925** 1 .820** .926**
Sig. (2-tailed) .000 .000 .000
V30 Pearsson Correlation .619** .820** 1 .687**
Sig. (2-tailed) .000 .000 .000
Mean Pearsson Correlation .975** .926** .687** 1
Sig. (2-tailed) .000 .000 .000
** Correlation is significant at the 0.01 level (2-tailed)
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endocrine- or trastuzumab therapy did not influence the
outcome, but the few events may have hampered the
possibility to evaluate this. In the present study, some
women received radiation to the internal mammary
nodes (IMN). Whether the IMN need to be included in
the CTV is not fully known. In the last years, many RT
centers have excluded RT to the lower IMN, in order to
avoid cardiac and lung toxicity. The meta-analysis in
Lancet, 2005, however demonstrated a benefit for post
mastectomy RT in women with positive LN and the
majority of these women received RT to the lower IMN
(21 of 23 studies) [1].
The LRRT-IMN group of our present series included
only nine patients. We used the same RT-technique
in both this and the previous study, and as could be
expected, there was no difference in radiological RP
(Table 1). CTV volumes minus IMN usually give lower
doses to the lung. Limiting the IMN irradiation to the
three upper intercostals spaces also lower the dose to
the heart. It is probably of great importance to reduce
radiation to organs at risk like heart and lung, when
adjuvant treatment is given. The average patient has a
long expected survival, but as there are many new sys-
temic therapies which may interact with RT this can
lead to additional side-effects. Aromatase Inhibitors (AI)
have replaced tamoxifen in many postmenopausal
patients.
The AI treatment in combination with RT is investi-
gated in a randomised trial presented in Lancet Oncol.
2010. The results suggested that AI can be used early,
but there still are doubts on potential long-term toxic
effects, mainly cardiac in combination with RT [26,27].
Genetic factors may also play a vitale role in treat-
ment. By identifying genetic factors associated with
radiosensitivity it will be easier to predict which patients
are at increased risk for complications secondary to
radiation treatment [11-13].
Even though symptomatic and radiological RP were
rare in our trial, they still could be of importance if they
prevail, as late changes could increase the risk of sec-
ondary lung cancer. This increased risk is seen in smo-
kers five years after RT [28].
To improve radiotherapy techniques and continue to
study pulmonary morbiditya n dQ o La f t e rR T ,i so f
great importance as breast cancer is a common disease
among women.
In conclusion, V20-constraints significantly reduced
post-RT radiological changes on chest X-ray in LRRT
for breast cancer. Symptomatic pneumonitis was,
furthermore, rare in the present study when this strategy
was used. There was no agreement between X-ray and
CT as diagnostic tools for post-RT in this trial, as the
lung changes typically were too limited for detection on
X-ray. V13 was most strongly related to radiological RP
on CT. V13 was stronger correlated to MLD than V20,
and may be an important metric in future trials on RT-
induced lung toxicity.
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